Zhejiang Orient Gene Biotech announced that its wholly-owned subsidiary, USA Haoyuan Health Biotechnology Co., Ltd., has recently obtained emergency use authorization (EUA) from the US FDA for the Healgen COVID-19/Flu A&B Ag Combo Rapid Test Cassette (Swab). The COVID-19 and influenza A/B antigen rapid combination detection kit (nasal swab) of USA Haoyuan has successfully completed performance evaluation and clinical verification in the United States, and has obtained the US FDA EUA emergency authorization.
东方生物：子公司新冠、甲乙流抗原快速检测试剂获得美国FDA EUA授权
Zhejiang Orient Gene Biotech: Subsidiaries' COVID-19, Influenza A/B Antigen Rapid Test Kits Obtain FDA EUA Authorization in USA
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.